Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: a structured summary of a study protocol for a randomised controlled trial

Catherine R. Hanna; Kevin G. Blyth; Glenn Burley; Samantha Carmichael; Carol Evans; Samantha Hinsley; Ibrahim Khadra; Saye Khoo; Liz-Anne Lewsley; Robert R. Jones; Raman Sharma; Andrea Taladriz-Sender; Emma C. Thomson; Janet T. Scott

doi:10.1186/s13063-020-04891-1

Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: a structured summary of a study protocol for a randomised controlled trial

Catherine R. Hanna, Kevin G. Blyth, Glenn Burley, Samantha Carmichael, Carol Evans, Samantha Hinsley, Ibrahim Khadra, Saye Khoo, Liz-Anne Lewsley, Robert R. Jones, Raman Sharma, Andrea Taladriz-Sender, Emma C. Thomson, Janet T. Scott

Research output: Contribution to journal › Letter › peer-review

7 Citations (Scopus)

23 Downloads (Pure)

Abstract

The GETAFIX trial will test the hypothesis that favipiravir is a more effective treatment for COVID-19 infection in patients who have early stage disease, compared to current standard of care. This study will also provide an important opportunity to investigate the safety and tolerability of favipiravir, the pharmacokinetic and pharmacodynamic profile of this drug and mechanisms of resistance in the context of COVID-19 infection, as well as the effect of favipiravir on hospitalisation duration and the post COVID-19 health and psycho-social wellbeing of patients recruited to the study.

Original language	English
Article number	935
Number of pages	3
Journal	Trials
Volume	21
DOIs	https://doi.org/10.1186/s13063-020-04891-1
Publication status	Published - 19 Nov 2020

Keywords

GETAFIX trial
Covid-19
patient study

Access to Document

10.1186/s13063-020-04891-1

Hanna-etal-Trials-2020-Glasgow-early-treatment-arm-favirpiravir-GETAFIX-for-adults-with-early-stage-COVID-19Final published version, 445 KBLicence: CC BY 4.0

Ibrahim Khadra
- ibrahim.khadrastrath.acuk
- Strathclyde Institute Of Pharmacy And Biomedical Sciences - Reader
Person: Academic

Cite this

Hanna, C. R., Blyth, K. G., Burley, G., Carmichael, S., Evans, C., Hinsley, S., Khadra, I., Khoo, S., Lewsley, L.-A., Jones, R. R., Sharma, R., Taladriz-Sender, A., Thomson, E. C., & Scott, J. T. (2020). Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials, 21, Article 935. https://doi.org/10.1186/s13063-020-04891-1

@article{1dc88238d3a54edea4332bbaf7955a54,

title = "Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: a structured summary of a study protocol for a randomised controlled trial",

abstract = "The GETAFIX trial will test the hypothesis that favipiravir is a more effective treatment for COVID-19 infection in patients who have early stage disease, compared to current standard of care. This study will also provide an important opportunity to investigate the safety and tolerability of favipiravir, the pharmacokinetic and pharmacodynamic profile of this drug and mechanisms of resistance in the context of COVID-19 infection, as well as the effect of favipiravir on hospitalisation duration and the post COVID-19 health and psycho-social wellbeing of patients recruited to the study.",

keywords = "GETAFIX trial, Covid-19, patient study",

author = "Hanna, {Catherine R.} and Blyth, {Kevin G.} and Glenn Burley and Samantha Carmichael and Carol Evans and Samantha Hinsley and Ibrahim Khadra and Saye Khoo and Liz-Anne Lewsley and Jones, {Robert R.} and Raman Sharma and Andrea Taladriz-Sender and Thomson, {Emma C.} and Scott, {Janet T.}",

year = "2020",

month = nov,

day = "19",

doi = "10.1186/s13063-020-04891-1",

language = "English",

volume = "21",

journal = "Trials",

issn = "1745-6215",

}

Hanna, CR, Blyth, KG, Burley, G, Carmichael, S, Evans, C, Hinsley, S, Khadra, I, Khoo, S, Lewsley, L-A, Jones, RR, Sharma, R, Taladriz-Sender, A, Thomson, EC & Scott, JT 2020, 'Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: a structured summary of a study protocol for a randomised controlled trial', Trials, vol. 21, 935. https://doi.org/10.1186/s13063-020-04891-1

TY - JOUR

T1 - Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19

T2 - a structured summary of a study protocol for a randomised controlled trial

AU - Hanna, Catherine R.

AU - Blyth, Kevin G.

AU - Burley, Glenn

AU - Carmichael, Samantha

AU - Evans, Carol

AU - Hinsley, Samantha

AU - Khadra, Ibrahim

AU - Khoo, Saye

AU - Lewsley, Liz-Anne

AU - Jones, Robert R.

AU - Sharma, Raman

AU - Taladriz-Sender, Andrea

AU - Thomson, Emma C.

AU - Scott, Janet T.

PY - 2020/11/19

Y1 - 2020/11/19

N2 - The GETAFIX trial will test the hypothesis that favipiravir is a more effective treatment for COVID-19 infection in patients who have early stage disease, compared to current standard of care. This study will also provide an important opportunity to investigate the safety and tolerability of favipiravir, the pharmacokinetic and pharmacodynamic profile of this drug and mechanisms of resistance in the context of COVID-19 infection, as well as the effect of favipiravir on hospitalisation duration and the post COVID-19 health and psycho-social wellbeing of patients recruited to the study.

AB - The GETAFIX trial will test the hypothesis that favipiravir is a more effective treatment for COVID-19 infection in patients who have early stage disease, compared to current standard of care. This study will also provide an important opportunity to investigate the safety and tolerability of favipiravir, the pharmacokinetic and pharmacodynamic profile of this drug and mechanisms of resistance in the context of COVID-19 infection, as well as the effect of favipiravir on hospitalisation duration and the post COVID-19 health and psycho-social wellbeing of patients recruited to the study.

KW - GETAFIX trial

KW - Covid-19

KW - patient study

U2 - 10.1186/s13063-020-04891-1

DO - 10.1186/s13063-020-04891-1

M3 - Letter

SN - 1745-6215

VL - 21

JO - Trials

JF - Trials

M1 - 935

ER -

Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: a structured summary of a study protocol for a randomised controlled trial

Abstract

Keywords

Access to Document

Fingerprint

Profiles

Ibrahim Khadra

Cite this